

Company name Shin Nippon Biomedical Laboratories, Ltd. Representative

Representative Chairman, President & CEO

Ryoichi Nagata

Listing TSE PRIME: ticker code 2395

Inquiries Managing Executive Officer, Senior Director,

Corporate Communications, Toshiyuki Iwata

+81 3 5565 6216 TEL

## Notice Regarding Distribution of Interim Dividends from Retained Earnings

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "the Company") announces that it was resolved at its Board of Directors' meeting today that interim dividends shall be paid from retained earnings to shareholders on the record date of September 30, 2023, as detailed below.

## 1. Details of interim dividends

	Resolved	Latest forecast (announced on May 8, 2023)	Interim dividends for the previous fiscal year ended March 31, 2023
Record date	September 30, 2023	Same as on the left	September 30, 2022
Dividends per share	¥20.00	Same as on the left	¥20.00
Total dividends	¥832 million	-	¥832 million
Effective date	November 30, 2023	-	November 30, 2022
Dividend resource	Retained earnings	-	Retained earnings

## 2. Reasons for payment of interim dividends

The Company's basic policy of stable profit distributions to shareholders, which is positioned as one of top management priorities, is to achieve the target of 30-40% in payout ratio on a consolidated basis, comprehensively considering Company's earning capacity and cash flow position. Based on this policy, the Board of Directors decided upon the payment of interim dividends of \(\frac{1}{2}\)2.00 per share, which is in line with the latest forecast of dividends for the fiscal year ending March 31, 2024.

## (Reference) Breakdown of annual dividends

	Dividends per share (¥: Japanese yen)		
Record date	End of 2 <sup>nd</sup> quarter	Year-end	Total
Fiscal year ending March 31, 2024	¥20.00 (Actual)	¥30.00 (Forecast)	¥50.00 (Forecast)
Fiscal year ended March 31, 2023	¥20.00	¥30.00	¥50.00